Misoprostol for Treatment of Postpartum Hemorrhage at Community-level Births in Egypt
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01619072|
Recruitment Status : Completed
First Posted : June 14, 2012
Last Update Posted : November 25, 2013
|Condition or disease||Intervention/treatment||Phase|
|Postpartum Hemorrhage||Other: Misoprostol + referral Other: Placebo + referral||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||82 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Controlled Community Study of the Effectiveness of Misoprostol for PPH Treatment at the Community Level (Home Births Attended by Primary Care Unit Staff) in Etay El Barood and Kafr El Dawar Districts (El Beheira Governorate), Egypt|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||October 2013|
Active Comparator: Misoprostol
800 mcg sublingual misoprostol + referral to higher level care
Other: Misoprostol + referral
800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
Placebo Comparator: Placebo
Placebo + referral to higher level care
Other: Placebo + referral
Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
- Change in hemoglobin measurement of >2 g/dL pre- to -post-delivery. [ Time Frame: Before delivery (at onset of labor), after delivery (2 to 4 days after delivery) ]Proportion of women with a change in hemoglobin of >2 g/dL pre- to post-delivery, as measured by the HemoCue machine at both time points.
- Proportion of women transferred to higher level care [ Time Frame: Within 2 to 4 days after delivery ]Proportion of women transferred to higher level care will be compared. The condition of the woman at time of transfer and arrival will also be noted.
- Proportion of women receiving additional interventions to treat PPH [ Time Frame: Within 2 to 4 days after delivery ]Proportion of women who receive any additional intervention (e.g. uterotonics, manual removal of placental fragments, bimanual compression, IV fluids given, surgical procedures, blood transfusion, etc.) provided either at deliver site or upon transfer to district hospital.
- Proportion of women with side effects [ Time Frame: Within 24 hours of delivery ]Proportion of women with observed side effects (including shivering/chills, fever, nausea, diarrhea or fainting). Reported severity of side effects (classified by provider as "mild, "moderate," "severe," ), duration of side effects and proportion of of women receiving additional care to manage side effects will also be assessed.
- Cost-effectiveness [ Time Frame: Within 2 to 4 days after delivery ]A cost-effectiveness analysis will be done to compare the two treatment arms. The analysis will factor in the cost of materials used, procedures/interventions performed, transfers, and training of providers.
- Proportion of women for whom intervention was correctly administered [ Time Frame: Within 1 hour of PPH diagnosis ]Proportion of women for whom treatment was administered as described in protocol (referral initiated and tablets administered to woman after PPH diagnosis made)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01619072
|Prinary Health Units|
|Etay El Barood and Kafr El Dawar districts, El Beheira governorate, Egypt|
|Principal Investigator:||Mohamed Cherine Ramadan, MD||El Galaa Teaching Hospital|
|Principal Investigator:||Nevine Hassanein, MD||Consultant|
|Principal Investigator:||Emad Darwish, MD||Alexandria University Faculy of Medicine|
|Principal Investigator:||Emad Ezzat, MD||Ministry of Health and Population|
|Principal Investigator:||Rasha Dabash, MPH||Gynuity Health Projects|